1. Scrip
  2. >>R&D
  3. >>Clinical Trials

Nordic Nanovector To Restructure After Discontinuing Lymphoma Trial

 
• By Alaric DeArment

The company still sees a potential future for Betalutin and hopes to partner the asset as it looks to focus on the rest of its pipeline.

Nordic Nanovector plans to restructure after discontinuing its NHL trial, PARADIGME • Source: Shutterstock

Nordic Nanovector ASA is angling to partner out the radioimmunoconjugate candidate Betalutin (177Lu lilotomab satetraxetan) as it plans to restructure following a negative interim analysis that led to the discontinuation of the Phase IIb PARADIGME trial of the drug in third-line follicular lymphoma (FL). The program had already faced recruitment challenges, and the company plans to focus its efforts on other assets in its pipeline as it seeks to reduce costs.

The Norway-based biotech said 5 July that it had chosen to discontinue PARADIGME following a comprehensive review and independent data...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

Takeda Prepares Ground For Oveporexton In Narcolepsy

 
• By Alaric DeArment

The drugmaker announced positive results from two Phase III trials for the drug in narcolepsy type 1 that analysts said bode well for the OX2R agonist class as a whole.

Leo Lands Another Big Pharma Pact With Boehringer Spevigo Deal

 
• By Kevin Grogan

Paying €90m upfront for rights to generalized pustular psoriasis drug.

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

More from R&D

Pipeline Watch: Ten Approvals And Two Phase III Readouts

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Capricor Gets Complete Response For DMD Cell Therapy

 
• By Joseph Haas

Seven weeks before its action date, Capricor got an FDA complete response for cell therapy deramiocel in DMD-related cardiomyopathy. It has a Phase III study nearing readout, though.

Bayer Bags First Global Okay For Hot Flashes Therapy

 
• By Kevin Grogan

Lynkuet will compete with Astellas's Veozah/Veoza